CVS$95.15

CVS Health Corporation exhibits concerning growth trends. While revenue has consistently grown, reaching $402,067 million in FY2025 and $407,905 million TTM, net income has been highly volatile, with significant declines in FY2022, FY2024, and FY2025, and a TTM decline of -44.47%. This indicates a lack of quality and consistency, as top-line growth is not translating to stable bottom-line expansion. Gross and operating margins have compressed significantly, with gross margin falling from 17.84% in FY2021 to 13.77% in FY2025, and operating margin from 4.56% to 1.16%. The large swings in 'Other Operating Expenses' and 'Interest Expense' (which turned positive in recent years) suggest one-off items impacting earnings durability. Assuming CVS is a healthcare services and retail company, these margin compressions are a red flag. The sustained decline in profitability despite revenue growth, coupled with volatile net income and deteriorating margins, points to significant risks and flags for investors.

CVS Health's balance sheet shows a mixed picture. Current assets have grown steadily from $60,008 million in FY21 to $74,714 million in FY25, outpacing current liabilities which increased from $67,807 million to $88,692 million over the same period. This indicates some pressure on working capital, though the company maintains a substantial asset base. Total liabilities have also risen, from $157,618 million to $178,156 million, but remain manageable relative to total assets of $253,538 million. Goodwill and other intangible assets constitute a significant portion of total assets, which is common in the healthcare sector due to acquisitions. Shareholders' equity has remained relatively stable, fluctuating around $75 billion, suggesting a consistent capital base despite increasing debt levels. Overall, the balance sheet appears stable but with some signs of increasing leverage.

CVS Health's operating cash flow (CFO) has shown a concerning downward trend from $18,265 million in FY2021 to $9,107 million in FY2024, before a modest recovery to $10,639 million in FY2025. The TTM CFO of $10,332 million indicates some stabilization but remains well below historical peaks. Free cash flow (FCF) mirrors this decline, dropping from $15,745 million to $6,326 million over the same period, with a TTM FCF of $7,394 million. Capital expenditures have been consistent, suggesting ongoing investment. However, significant investing cash outflows, particularly in FY2023 due to business acquisitions, have impacted overall cash generation. Financing activities show a mix of debt management and consistent dividend payments, with share repurchases being volatile. The overall cash flow profile suggests a company navigating significant operational and investment shifts, leading to inconsistent cash generation.

CVS Health Corporation exhibits mixed financial health. Liquidity, as indicated by the current and quick ratios, has fluctuated but remains below 1.0, suggesting potential short-term solvency challenges. Leverage has generally increased, with the Debt/EBITDA ratio rising significantly from 4.27 in FY2021 to 9.52 currently, indicating a growing reliance on debt relative to earnings. Efficiency metrics show improvement, with asset turnover and inventory turnover steadily increasing, suggesting better utilization of assets. However, profitability and returns have been inconsistent. ROE and ROA have seen significant fluctuations and a notable decline in the most recent periods, with ROE falling from 11.01% in FY2021 to 3.79% currently, and ROIC also trending downwards. This indicates weakening returns on capital despite improved operational efficiency.

CVS Health shows a mixed growth trajectory. Historically, revenue growth was robust, peaking at 10.88% in FY 2023, but estimates project a deceleration to 2.27% by FY 2026 before a slight recovery. EPS has been highly volatile, with significant contractions in FY 2022, FY 2024, and FY 2025, followed by a projected sharp rebound in FY 2026. This volatility suggests potential margin pressures or one-off events impacting profitability. Forward P/E ratios for FY 2026 and FY 2027 are 13.15 and 11.51, respectively, which appear reasonable given the projected growth rates, especially the strong EPS recovery in FY 2026. Analyst sentiment is positive, with a "Strong Buy" consensus from 18 analysts and a stable recommendation trend. The price target range indicates confidence, with an average of $98.06. However, the inconsistent EPS growth trajectory tempers the overall outlook.